Navigation Links
Estrogen found to increase growth of the most common childhood brain tumor
Date:2/17/2009

CINCINNATIUniversity of Cincinnati (UC) researchers have discovered that estrogen receptors are present in medulloblastomathe most common type of pediatric brain tumorleading them to believe that anti-estrogen drug treatments may be beneficial in limiting tumor progression and improving patients' overall outcome.

This research is being published in the March 2009 edition of Endocrinology.

In estrogen-responsive cancerssuch as breast cancerestrogen receptors act to increase tumor growth and progression. Estrogen receptors are also the most important drug targets for the treatment of breast cancer.

"Current therapies for medulloblastoma involve cranial surgery, chemotherapy and radiation," says Scott Belcher, PhD, principal investigator of the study. "This discovery suggests that we may be able to use anti-hormone or estrogen drug therapieslike those used to treat breast cancersto limit progression of these childhood brain tumors and to decrease the adverse side-effects of radiation treatment."

Medulloblastoma, or MD, is a highly malignant brain tumor, most commonly diagnosed in children.

Patients with MD typically have a five-year survival rate between 50 and 70 percent, and survivors who endure current, more aggressive treatments face an increased risk for chronic illnesses such as diabetes or cardiovascular disease later in life.

Belcher, an associate professor in the department of pharmacology and cell biophysics at UC, and his team examined tumor tissue from 22 patients between the ages of 6 months and 18 years.

They found evidence of estrogen receptors, particularly estrogen receptor beta, in the cancerous cells of every tumor analyzed.

"MD manifests when specific neuron precursors in the brain fail to stop normally differentiating into mature neurons," Belcher says. "Our previous studies showed that estrogen receptors are regulated during differentiation of these neuronal precursors. MD growth and tumor cell formation can be blocked by inhibiting the activity of these receptors."

Belcher said these results demonstrate the importance of "bench to bedside" discoveries.

"We started in tumor cells and then moved to animal models of MD and found that we could stop the growth of tumors using anti-estrogen therapies," he says. "We've been able to identify these receptors in humans. We are now hoping that our basic developmental biology findings can take the final step by stopping the growth of these tumors in humans."

"We believe that development of rational anti-estrogen drug therapies for this highly malignant cancer is a possibility and could improve the lives of many children and adult survivors," he continues.


'/>"/>

Contact: Katie Pence
katie.pence@uc.edu
513-558-4561
University of Cincinnati
Source:Eurekalert

Related medicine news :

1. New link between estrogen and breast cancer
2. UCLA study identifies designer estrogen as potential MS drug
3. Cholesterol byproduct blocks heart health benefits of estrogen
4. Gene May Influence Breast Cancer-Estrogen Link
5. Duramed Launches New Indication for ENJUVIA(TM) (Synthetic Conjugated Estrogens, B) at North American Menopause Society Annual Meeting
6. Estrogen Levels in Blood Predict Breast Cancers Return
7. Mitochondria play role in pathogenesis of AD and estrogen-induced neuroprotection
8. New study finds adverse effects of estrogen replacement therapy are related to the dose
9. Estrogen Supplements May Raise Odds of Benign Breast Disease
10. Estrogen therapy increases benign breast disease risk
11. Previously unseen switch regulates breast cancer response to estrogen
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... The Visiting Nurse Association (VNA) ... a collection of specialty vendors and unique items from across the nation, this holiday-themed ... and wellness services offered by the VNA. The boutique will be open Saturday, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Coveros, ... Development, has been awarded a contract by the Center for Medicare and Medicaid ... to accelerate the enterprise use of Agile methodologies in a consistent and high ...
(Date:10/12/2017)... ... 2017 , ... Planet Fitness, one of the largest and fastest growing franchisors ... a flagship location in Covington, LA at 401 N. U.S. Highway 190, in January ... Office Depot in the Holiday Square shopping center. Its location allows it to serve ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... of Michigan’s 2017 Best and Brightest in Wellness® by Best and Brightest. OnSite ... program on Friday, Oct. 20 from 7:30 a.m. to 2 p.m. at the ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... AVACEN Medical , Inc. (AVACEN) announced that Frost & ... Innovation Award for Its fibromyalgia pain management device. The ... market research by Frost & Sullivan,s industry experts. ... product, the AVACEN 100, offers a safe and effective solution ... ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
(Date:10/10/2017)... EXTON, Pa. , Oct. 10, 2017   ... leader in innovative solutions for injectable drug administration, today ... of West,s ID Adapter for improving the intradermal administration ... the Fourth Skin Vaccination Summit in May 2017 by ... Team Lead, Polio Department, World Health Organization (WHO), and ...
Breaking Medicine Technology: